Does the media prefer CRSP or ALLO?

In the previous week, Allogene Therapeutics had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Allogene Therapeutics and 3 mentions for CRISPR Therapeutics. Allogene Therapeutics' average media sentiment score of 0.58 beat CRISPR Therapeutics' score of 0.34 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or CRSP?

In the previous week, Axsome Therapeutics had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.34 beat CRISPR Therapeutics' score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRSP or BEAM?

In the previous week, Beam Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 3 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 1.07 beat CRISPR Therapeutics' score of 0.34 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or EDIT?

In the previous week, Editas Medicine had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Editas Medicine and 3 mentions for CRISPR Therapeutics. Editas Medicine's average media sentiment score of 0.64 beat CRISPR Therapeutics' score of 0.34 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or KALA?

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 3 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.34 beat KALA BIO's score of -1.17 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

CRISPR Therapeutics (CRSP) Competitors

$58.12 -1.69 (-2.83%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$58.73 +0.61 (+1.05%)

As of 08:43 AM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? CRISPR Therapeutics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

CRISPR Therapeutics presently has a consensus target price of $68.06, indicating a potential upside of 17.09%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 295.24%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

In the previous week, Allogene Therapeutics had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Allogene Therapeutics and 3 mentions for CRISPR Therapeutics. Allogene Therapeutics' average media sentiment score of 0.58 beat CRISPR Therapeutics' score of 0.34 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Allogene Therapeutics	N/A	-50.04%	-36.74%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Allogene Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,601.03	-$581.60M	-$4.76	N/A
Allogene Therapeutics	$4.64M	156.36	-$190.89M	-$0.67	N/A

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 3 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.34 beat CRISPR Therapeutics' score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics presently has a consensus price target of $267.60, indicating a potential upside of 28.64%. CRISPR Therapeutics has a consensus price target of $68.06, indicating a potential upside of 17.09%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Axsome Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Axsome Therapeutics has a net margin of -24.68% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	14.03	-$183.17M	-$3.75	N/A
CRISPR Therapeutics	$3.51M	1,601.03	-$581.60M	-$4.76	N/A

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 12 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 17.09%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 72.60%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Beam Therapeutics has a net margin of -54.75% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,601.03	-$581.60M	-$4.76	N/A
Beam Therapeutics	$156.04M	18.79	-$79.99M	-$0.86	N/A

In the previous week, Beam Therapeutics had 3 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 3 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 1.07 beat CRISPR Therapeutics' score of 0.34 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

CRISPR Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus target price of $68.06, indicating a potential upside of 17.09%. Editas Medicine has a consensus target price of $5.50, indicating a potential upside of 87.07%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,601.03	-$581.60M	-$4.76	N/A
Editas Medicine	$40.52M	11.14	-$160.06M	-$0.75	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Editas Medicine had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Editas Medicine and 3 mentions for CRISPR Therapeutics. Editas Medicine's average media sentiment score of 0.64 beat CRISPR Therapeutics' score of 0.34 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

Summary

Editas Medicine beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

CRISPR Therapeutics (NASDAQ:CRSP) and KALA BIO (NASDAQ:KALA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 3 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.34 beat KALA BIO's score of -1.17 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

KALA BIO has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,601.03	-$581.60M	-$4.76	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

CRISPR Therapeutics presently has a consensus price target of $68.06, suggesting a potential upside of 17.09%. KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 137,780.41%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, meaning that its share price is 326% less volatile than the broader market.

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
KALA BIO	N/A	-332.67%	-64.57%

Summary

CRISPR Therapeutics beats KALA BIO on 11 of the 15 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.78B	$4.02B	$7.34B	$12.83B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-12.21	11.53	268.95	24.06
Price / Sales	1,601.03	1,280.36	597.99	78.35
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	3.22	16.92	13.01	6.15
Net Income	-$581.60M	-$12.52M	$3.46B	$347.39M
7 Day Performance	8.53%	1.45%	0.97%	-0.97%
1 Month Performance	20.71%	4.78%	3.85%	1.05%
1 Year Performance	10.03%	58.35%	26.48%	19.63%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.6096 of 5 stars	$58.12 -2.8%	$68.06 +17.1%	+9.5%	$5.78B	$3.51M	N/A	460
ALLO Allogene Therapeutics	2.1038 of 5 stars	$2.08 +1.5%	$8.30 +299.0%	+98.1%	$717.91M	$20K	N/A	310
AXSM Axsome Therapeutics	3.4672 of 5 stars	$216.27 +1.2%	$267.60 +23.7%	+77.8%	$11.33B	$638.50M	N/A	380	Positive News Analyst Upgrade
BEAM Beam Therapeutics	2.1361 of 5 stars	$27.10 +1.3%	$49.00 +80.8%	+76.8%	$2.80B	$139.74M	N/A	510	Positive News Gap Down
EDIT Editas Medicine	2.3777 of 5 stars	$2.84 +0.7%	$5.40 +90.1%	+10.1%	$436.17M	$47.01M	N/A	230	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Do analysts prefer CRSP or ALLO?

Which has more risk & volatility, CRSP or ALLO?

Does the media prefer CRSP or ALLO?

Is CRSP or ALLO more profitable?

Do institutionals & insiders have more ownership in CRSP or ALLO?

Which has preferable valuation and earnings, CRSP or ALLO?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Do insiders & institutionals believe in AXSM or CRSP?

Does the media refer more to AXSM or CRSP?

Do analysts rate AXSM or CRSP?

Which has more volatility & risk, AXSM or CRSP?

Is AXSM or CRSP more profitable?

Which has better earnings and valuation, AXSM or CRSP?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, CRSP or BEAM?

Do insiders and institutionals have more ownership in CRSP or BEAM?

Do analysts rate CRSP or BEAM?

Is CRSP or BEAM more profitable?

Which has preferable earnings and valuation, CRSP or BEAM?

Does the media refer more to CRSP or BEAM?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Which has more risk and volatility, CRSP or EDIT?

Do analysts prefer CRSP or EDIT?

Which has higher valuation and earnings, CRSP or EDIT?

Do institutionals & insiders believe in CRSP or EDIT?

Does the media refer more to CRSP or EDIT?

Is CRSP or EDIT more profitable?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Do insiders & institutionals have more ownership in CRSP or KALA?

Does the media favor CRSP or KALA?

Which has preferable earnings & valuation, CRSP or KALA?

Do analysts rate CRSP or KALA?

Which has more volatility & risk, CRSP or KALA?

Is CRSP or KALA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools